News | January 6, 2025

Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD) VGA039 is potentially the first subcutaneous therapy that addresses all types of VWD and has a convenient dosing regimen SOUTH SAN FRANCISCO, CA, January 6, 2025 – Star...